PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
April 1, 2026Current Oncology1 citationsOpen Access

Robotic Partial Cystectomy and Extended Pelvic Lymph Node Dissection for Node-Positive Urachal Adenocarcinoma in a 34-Year-Old Woman: A Case Report

View Full Paper
SHSusanne HerrmannCGChristian GilfrichSSStefan Siepmann

Key Points

  • This case report aims to highlight the surgical management of a rare case of urachal adenocarcinoma with node involvement.
  • Performed robot-assisted partial cystectomy and extended bilateral pelvic lymph node dissection.
  • Maintained umbilical preservation after confirming negative margins.
  • Conducted comprehensive genetic analysis using next-generation sequencing.
  • Final pathology indicated 4.5 cm enteric-type urachal adenocarcinoma with pT3a pN2 classification.
  • No postoperative complications or treatment-limiting toxicity observed.
  • Patient showed normalization of carcinoembryonic antigen and carbohydrate antigen 19-9 levels.

Abstract

Urachal carcinoma is a rare and aggressive malignancy for which standardized management remains limited, particularly in patients with locally advanced and node-positive disease. We report the case of a 34-year-old woman with urachal adenocarcinoma involving the bladder dome and radiographically suspicious pelvic lymph nodes who underwent robot-assisted partial cystectomy with urachal resection and extended bilateral pelvic lymph node dissection. Because there was no clinical, radiologic, or intraoperative evidence of umbilical involvement, the umbilicus was preserved after preoperative counseling and intraoperative confirmation of a negative proximal margin. Final pathology demonstrated a 4.5 cm enteric-type urachal adenocarcinoma, pT3a pN2 (2/17), with lymphovascular invasion, perineural invasion, and negative surgical margins. Immunohistochemistry and DNA- and RNA-based next-generation sequencing showed microsatellite stability, mismatch-repair proficiency, low tumor mutational burden, and no actionable genomic alteration. Given the absence of an established adjuvant standard, the multidisciplinary tumor board selected adjuvant FOLFOX as a non-standard postoperative strategy based on the overall clinicopathologic context. The patient remained continent, experienced no postoperative complications or treatment-limiting toxicity, and showed normalization of carcinoembryonic antigen and carbohydrate antigen 19-9 levels. This case provides a carefully contextualized example of transparent surgical reasoning and restrained multidisciplinary management in a rare malignancy with limited prospective evidence.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Herrmann et al. (2026) studied this question.

synapsesocial.com/papers/69ccb66716edfba7beb88056https://doi.org/10.3390/curroncol33040190
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Presentation and survival for urachal cancer: Findings from a nationwide multicenter cohort study in Norway2025 · 2 citations
  2. 2Urachal Carcinoma Shares Genomic Alterations with Colorectal Carcinoma and May Respond to Epidermal Growth Factor Inhibition2016 · 90 citations
  3. 3Phase I trial of the MET inhibitor tepotinib in Japanese patients with solid tumors2020 · 30 citations
  4. 4Precision Oncology Approach for Urachal Carcinoma: A Clinical Case Report2024 · 6 citations
  5. 5Treatment approaches for urachal cancer: Use of immunotherapy and targeted therapies2023 · 7 citations